v3.25.4
Revenue (Additional Information) (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jan. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]        
Other current liabilities   $ 2,610 $ 1,926  
Otsuka Agreement [Member]        
Disaggregation of Revenue [Line Items]        
Revenue Related To Certain Research And Development   0 300  
Research And Development Services Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Revenue Related To Certain Research And Development   4,000 0  
Performance obligation   1,500    
Other current liabilities   1,500 $ 700  
Research And Development Services Revenue [Member] | Customer One [Member]        
Disaggregation of Revenue [Line Items]        
Research and development service revenue   1,600    
Research And Development Services Revenue [Member] | Customer Two [Member]        
Disaggregation of Revenue [Line Items]        
Research and development service revenue   1,500    
Research And Development Services Revenue [Member] | Customer Three [Member]        
Disaggregation of Revenue [Line Items]        
Research and development service revenue   $ 700    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Research And Development Services Revenue [Member] | Customer One [Member]        
Disaggregation of Revenue [Line Items]        
Concentration Risk, Percentage   10.00% 10.00% 10.00%
Rizafilm [Member] | Supply Agreement [Member]        
Disaggregation of Revenue [Line Items]        
Additional revenue recognition for sales licensing and intellectual property $ 500      
Performance obligation $ 200      
License agreement terms   the Supply Agreement, subject to approval by the FDA, Nualtis will serve as the sole manufacturer of Rizafilm's products over a five year term with an automatic renewal option for an additional five years unless either party provides sufficient written notice.    
Contract with customer liability, revenue recognized   $ 200